ClinicalTrials.gg
RecruitingNCT04988672OPTIMISERUpdated Oct 6, 2023

OPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction

An observational study in Myocardial Infarction, Myocardial Ischemia and STEMI, sponsored by Luzerner Kantonsspital. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Luzerner Kantonsspital · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.

Planned enrollment
6th of 18
4,000 · median 1,526
Started
2021
with 9 others
Observational
18 of 69
5 open now
Primary completion
2026-12
later than 4 of 19 live
Registered
53rd of 69
by date

Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 6th largest by planned enrollment of the 18 observational ones that give a count, is one of 10 that started in 2021, is one of 18 observational ones, reaches primary completion later than 4 of the 19 other live ones, and was the 53rd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Myocardial Infarction with a site in Switzerland, or all of them as a file.
02

Study summary

The purpose of the OPTIMISER Registry is to prospectively and retrospectively collect baseline, clinical and procedural data in patients who present with AMI and are treated with PCI as well as prospectively collect the clinical outcome data. Outcomes will be compared in different clinical subgroups. The impact of PCI in AMI in general as well as cardiovascular outcomes after AMI will be assessed.

Read the detailed description
  • To assess procedural success and clinical outcomes among persons with AMI, who undergo PCI and/ or CABG for AMI (STEMI or NSTEMI)

    1. Periprocedural outcomes/ complications, which will be analyzed, represent: final result (e.g. TIMI flow), stent expansion, dissections, perforations, prevalence of thrombus (assessed by angiography and intravascular imaging)
    2. Short and long-term clinical outcomes of interest including: new AMI, unstable angina (UA), stent-/scaffold thrombosis, target lesion failure, target vessel revascularization, ischemia driven revascularization, repeat hospitalization, new/worsening heart failure, cardiogenic shock, stroke, bleedings, cardiovascular death and all-cause death.
  • To describe procedural and clinical performance of various balloon, stent and scaffold devices implanted in patients presenting with AMI during the afore mentioned period
  • To study the impact of different devices and strategies used for lesion preparation and PCI optimization strategies among patients undergoing PCI
  • To describe early and late angiographic and OCT-findings among coronary artery disease in patients with AMI treated with various metallic stent and scaffold devices
  • To assess possible predictors for coronary stent implantation or device failure
  • To evaluate the impact of different antithrombotic regimens on patient clinical outcomes
  • To study procedural and clinical outcomes among CAD patients requiring hemodynamic support using mechanical devices.
  • To describe economic implications (cost-effectiveness) of various interventional treatments for CAD.
03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In an all-comers design, virtually any AMI patient treated with PCI or CABG at the Cardiology Division of Lucerne Cantonal Hospital and giving consent may be included. We expect a total inclusion rate of around 400 patients per year at the LUKS. The prospective recruitment is planned to continue for 10 years, which results in 4000 patients in the prospective arm. In addition, a retrospective arm will include a random sample of 500 patients who presented with AMI and were treated with PCI or CABG in the 5 years prior to study start (2016-2020).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject >18 years of age
  • Individuals who are newly diagnosed with AMI or have been diagnosed with AMI (STEMI or NSTEMI) within the last 5 years (since 2016).
  • Subjects must be willing to sign a patient (PIC) OR a patient ́s relative/ proxy are willing to provide PIC or patients have signed the General Consent (GK).

Exclusion criteria

Exclusion Criteria:

  • Patient unwilling or unable to provide
  • Patients with no ACS/AMI (e.g. Takotsubo cardiomyopathy, acute heart failure not related to AMI)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Rate of major adverse cardiac and cerebrovascular events (MACCE) (including new AMI, stroke or cardiovascular death) at 1 year

    Time frame: at 1 year

Secondary outcomes

  1. Rate of major adverse cardiac and cerebrovascular events (MACCE)

    Time frame: 1, 2, 5 and 10 years

  2. Rate of new AMI

    Time frame: 1, 2, 5 and 10 years

  3. Rate of TIA or stroke

    Time frame: 1, 2, 5 and 10 years

  4. Rate of stent thrombosis

    Time frame: 1, 2, 5 and 10 years

  5. Rate of target vessel revascularization

    Time frame: 1, 2, 5 and 10 years

  6. Rate of target lesion failure

    Time frame: 1, 2, 5 and 10 years

  7. Rate of ischemia-driven revascularization

    Time frame: 1, 2, 5 and 10 years

  8. Rate of unstable angina

    Time frame: 1, 2, 5 and 10 years

  9. Rate of rehospitalization for recurrent angina

    Time frame: 1, 2, 5 and 10 years

  10. Rate of hospitalization for heart failure

    Time frame: 1, 2, 5 and 10 years

  11. Rate of rehospitalisation for heart failure, resuscitated cardiac arrest or implantable cardioverter-defibrillator (ICD) implantation at follow- up.

    Time frame: 1, 2, 5 and 10 years

  12. Rate of cardiovascular mortality

    Time frame: 1, 2, 5 and 10 years

  13. Rate of all-cause mortality

    Time frame: 1, 2, 5 and 10 years

  14. Rate of bleeding events (access site or non-access site related) according to the BARC classification.

    Time frame: 1, 2, 5 and 10 years

  15. Rate of vascular complications (according to VARC criteria)

    Time frame: 1, 2, 5 and 10 years

  16. Rate of new York Heart Association (NYHA) class

    Time frame: 1, 2, 5 and 10 years

  17. Rate of cardiogenic shock

    Time frame: 1, 2, 5 and 10 years

  18. Rate of acute renal failure

    Time frame: 1, 2, 5 and 10 years

  19. Rate of new atrial fibrillation

    Time frame: 1, 2, 5 and 10 years

  20. Rate of new ventricular arrhythmias

    Time frame: 1, 2, 5 and 10 years

  21. Rate of major adverse limb events (MALE)

    Time frame: 1, 2, 5 and 10 years

  22. Rate of periprocedural complications (e.g. coronary perforations, no- reflow)

    Time frame: 1, 2, 5 and 10 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tersalvi G, Attinger-Toller A, Kalathil D, Winterton D, Cioffi GM, Madanchi M, Seiler T, Stadelmann M, Goffredo F, Fankhauser P, Moccetti F, Wolfrum M, Toggweiler S, Bloch A, Kobza R, Cuculi F, Bossard M. Trajectories of Cardiac Function Following Treatment With an Impella Device in Patients With Acute Anterior ST-Elevation Myocardial Infarction. CJC Open. 2022 Nov 5;5(1):77-85. doi: 10.1016/j.cjco.2022.11.002. eCollection 2023 Jan. PubMed 36700188 ↗
  • Cioffi GM, Madanchi M, Bossard M, Cuculi F. Deferring stent optimization in stent thrombosis: A novel approach for STEMI management-Insights from a case series. Clin Case Rep. 2021 Feb 13;9(3):1150-1154. doi: 10.1002/ccr3.3697. eCollection 2021 Mar. PubMed 33768799 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 298 non-industry observational studies under Myocardial Infarction, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 140. This study's planned 71 months is above that.

Counting every sponsor, half of 335 studies reached it within 48 months; a quarter within 18 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2021
First posted
Aug 3, 2021
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04988672
Lead sponsor
Luzerner Kantonsspital
Responsible party
Matthias Bossard (Co-principal Investigator, Luzerner Kantonsspital) — Principal investigator
First posted
Aug 3, 2021
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Oct 6, 2023

Study contacts

Florim Cuculi, M.D.
Contact
florim.cuculi@luks.ch
+41412052134
Matthias Bossard, M.D.
Contact
matthias.bossard@luks.ch
+41412051477
Florim Cuculi, M.D.
principal investigator · Luzerner Kantonsspital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion